Core Viewpoint - Embecta Corp reported a decline in revenues for the first quarter of fiscal year 2025, driven by unfavorable changes in volume and foreign currency translation, while also updating its financial guidance for the year [2][10][9]. Financial Highlights - Total revenues for the three months ended December 31, 2024, were $261.9 million, a decrease of 5.6% from $277.3 million in the same period of 2023 [7][9]. - U.S. revenues decreased by 4.6% on both reported and adjusted constant currency bases, while international revenues fell by 6.6% reported and 5.1% adjusted [6][7]. - Gross profit was $157.1 million with a margin of 60.0%, down from $185.9 million and 67.0% in the prior year [7][16]. - Adjusted net income was $38.3 million, or $0.65 per diluted share, compared to $35.3 million, or $0.61 per diluted share in the prior year [7][29]. Strategic Highlights - The company is on track to complete its restructuring plan related to the discontinuation of the insulin patch pump program by the end of the first half of fiscal year 2025 [2][7]. - A brand transition plan is set to launch in the second half of the fiscal year, starting in the U.S. and Canada [2][7]. - Progress is being made on GLP-1 initiatives to enhance patient access to pen needles for GLP-1 pen injectors [2][7]. Updated Financial Guidance - For fiscal year 2025, Embecta expects reported revenues to be between $1,075 million and $1,092 million, down from previous guidance of $1,093 million to $1,110 million [10]. - Adjusted constant currency revenue growth is anticipated to be between (2.5)% and (1.0)% [10]. - Adjusted gross margin is expected to remain between 63.25% and 64.25% [10]. Balance Sheet and Liquidity - As of December 31, 2024, the company had approximately $216.7 million in cash and equivalents, with total debt principal outstanding at $1.569 billion [11][19]. - The company declared a quarterly cash dividend of $0.15 per share, payable on March 14, 2025 [12][19].

PARSIPPANY, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 6, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast c ...

Stocks hitting their 52-week high and delivering consistent performance offer attractive opportunities to investors while building a portfolio. This is because stocks near that level are perceived to be winners. However, stocks touching a new 52-week high are often predisposed to profit-taking, resulting in pullbacks and trend reversals. Moreover, given the high price, investors often wonder if the stock is overpriced. While the speculations are not absolutely baseless, all stocks hitting a 52-week high are ...

PARSIPPANY, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 7:30 a.m. PT / 10:30 a.m. ET. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at investors.embecta.com. About embecta embecta is a global diabetes care company that is leveraging its nearly 100-year ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission file number 001-41186 EMBECTA CORP. (Exact name of registrant as specified in its charter) Delaware 87-1583942 (State or other jurisdiction of incorporatio ...

Robert F. Abbott has been investing his family’s accounts since 1995, and in 2010 added options, mainly covered calls and collars with long stocks. He is a freelance writer, and his projects include a website that provides information for new and intermediate-level mutual fund investors. A resident of Airdrie, Alberta, Canada, Robert has earned Bachelor of Arts and Master of Business Administration (MBA) degrees.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the co ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Embecta Corp. (EMBC) : This medical device company has seen the Zacks Consensus Estimate for its current year earnings increasing 14.9% over the last 60 days.Toast, Inc. (TOST) : This cloud-based digital technology platform provider has seen the Zacks Consensus Estimate for its current year earnings increasing 120% over the last 60 days.monday.com Ltd. (MNDY) : This software development company has seen the Zacks Consensus Estimate for ...

Financial Data and Key Metrics Changes - In Q4 2024, Embecta's adjusted revenues totaled $290.2 million, representing a 4.1% increase compared to the prior year period, or 3.3% excluding contract manufacturing revenue [40] - For the full year 2024, adjusted revenues were approximately $1,127 million, reflecting a 1.1% increase on an adjusted constant currency basis [45] - Adjusted EBITDA for Q4 2024 was approximately $73 million, with a margin of 25.2%, compared to $79.6 million and 28.2% in the prior year [59] - GAAP net income for Q4 2024 was $14.6 million, or $0.25 per diluted share, compared to $6 million and $0.10 in the prior year [57] Business Line Data and Key Metrics Changes - Pen needle revenue grew approximately 2.8%, syringe revenue grew approximately 4.8%, safety products grew approximately 5.8%, and contract manufacturing grew approximately 96% in Q4 2024 [41] - For the full year, pen needle and safety product lines grew approximately 2.6% and 2.5%, respectively, while syringe product lines declined approximately 9% [46] Market Data and Key Metrics Changes - International revenue in Q4 totaled $122.8 million, a 3.1% decline on an adjusted constant currency basis, primarily due to timing of orders in China and the impact of the Italian payback measure [43] - U.S. revenues for the full year totaled $607.2 million, an increase of 1% on an adjusted constant currency basis, driven by favorable pricing dynamics [47] Company Strategy and Development Direction - The company announced a restructuring plan aimed at streamlining operations and reducing costs, including the discontinuation of the insulin patch pump program [16] - Future strategic priorities include strengthening the core business, expanding the product portfolio, and increasing financial flexibility [24] - The company plans to focus on GLP-1 therapies and has launched a new small pack pen needle product in Germany [30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced, including historic inflation and supply chain issues, which impacted margins by approximately 500 basis points [14] - The company anticipates that pricing will become a headwind in 2025 due to the renewal of agreements [49] - Management expressed confidence in the company's ability to navigate the evolving market landscape and capitalize on growth opportunities [96] Other Important Information - The company incurred approximately $63 million in expenses related to the patch pump program during fiscal year 2024 [73] - A debt paydown plan was initiated to enhance financial flexibility moving forward [15] Q&A Session Summary Question: Inquiry about capital allocation priorities post patch pump decision - Management emphasized that the primary focus is on debt paydown to create financial flexibility for potential M&A opportunities [87][88] Question: Clarification on potential impacts from tariffs and macroeconomic factors - Management noted that a small portion of U.S. revenue comes from products manufactured in China and will monitor tariff developments closely [96] Question: Discussion on residual value of the patch pump and future opportunities - Management stated that while no viable options surfaced for monetizing the patch pump, they remain open to future discussions if interest arises [114] Question: Inquiry about cost savings from restructuring - Management confirmed that the restructuring is primarily tied to the discontinuation of the patch pump, aligning with the anticipated savings [116]

| --- | --- | |------------------------------|-------| | | | | | | | | | | Earnings Conference Call | | | | | | Fiscal Q4 and Full Year 2024 | | | | | | November 26, 2024 | | Forward-Looking Statements Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations reg ...

On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago.The company reported quarterly sales of $286.1 million, up 1.5% year over year, beating the consensus of $277 million.“We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics…Additionally, the recent launch of our small-pack GLP-1 needle ...